Ameriprise’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-99,050
| Closed | -$479K | – | 3781 |
|
|
2020
Q1 | $479K | Buy |
99,050
+28,600
| +41% | +$185K | ﹤0.01% | 3150 |
|
|
2019
Q4 | $749K | Buy |
70,450
+14,900
| +27% | +$148K | ﹤0.01% | 3187 |
|
|
2019
Q3 | $579K | Buy |
55,550
+12,100
| +28% | +$158K | ﹤0.01% | 3254 |
|
|
2019
Q2 | $666K | Sell |
43,450
-1,500
| -3% | -$21.7K | ﹤0.01% | 3230 |
|
|
2019
Q1 | $578K | Hold |
44,950
| – | – | ﹤0.01% | 3244 |
|
|
2018
Q4 | $427K | Sell |
44,950
-2,280
| -5% | -$29.6K | ﹤0.01% | 3244 |
|
|
2018
Q3 | $784K | Sell |
47,230
-1,600
| -3% | -$25.7K | ﹤0.01% | 3160 |
|
|
2018
Q2 | $783K | Buy |
48,830
+220
| +0.5% | +$3.93K | ﹤0.01% | 3093 |
|
|
2018
Q1 | $743K | Sell |
48,610
-2,470
| -5% | -$38.5K | ﹤0.01% | 3089 |
|
|
2017
Q4 | $797K | Buy |
51,080
+7,200
| +16% | +$96.3K | ﹤0.01% | 3063 |
|
|
2017
Q3 | $487K | Buy |
43,880
+6,000
| +16% | +$56.4K | ﹤0.01% | 3230 |
|
|
2017
Q2 | $348K | Sell |
37,880
-6,020
| -14% | -$50.2K | ﹤0.01% | 3365 |
|
|
2017
Q1 | $375K | Buy |
43,900
+3,500
| +9% | +$31.9K | ﹤0.01% | 3269 |
|
|
2016
Q4 | $433K | Buy |
+40,400
| New | +$489K | ﹤0.01% | 3338 |
|
|
2014
Q4 | – | Sell |
-40
| Closed | – | – | 4677 |
|
|
2014
Q3 | $0 | Buy |
40
+30
| +300% | +$369 | ﹤0.01% | 5941 |
|
|
2014
Q2 | $0 | Buy |
+10
| New | +$153 | ﹤0.01% | 5701 |
|
|
2013
Q4 | – | Sell |
-570
| Closed | -$26K | – | 5522 |
|
|
2013
Q3 | $26K | Hold |
570
| – | – | ﹤0.01% | 4242 |
|
|
2013
Q2 | $14K | Buy |
+570
| New | +$9.08K | ﹤0.01% | 4552 |
|
Ameriprise's STML Position: Q2 2020 in Review
Ameriprise sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 99,050 shares — an estimated $479K sold.
Ameriprise first reported a position in STML in Q2 2013 and held it in 18 quarters. The position peaked at $797K in Q4 2017. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Ameriprise reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Ameriprise sold 99,050 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $479K.
- Ameriprise first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
- Ameriprise's Stemline Therapeutics, Inc. position peaked at $797K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Ameriprise's 13F filing for Q2 2020, filed 14 Aug 2020.